

Priv.-Doz. Dr. med. Dr. med. habil Tobias R. Koppara

Wissenschaftliche Publikationen (Selektion)

Kumulative Impactpunkte > 200

1. [Long-term clinical outcomes after drug eluting stent implantation with and without stent overlap.](#)
Coughlan JJ, Aytekin A, Koch T, Wiebe J, Lenz T, Cassese S, Joner M, **Koppara T**, Xhepa E, Ibrahim T, Fusaro M, Laugwitz KL, Schunkert H, Kastrati A, Kufner S.
Catheter Cardiovasc Interv. 2021 Sep 6. doi: 10.1002/ccd.29944.
PMID: 34487415
2. [Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus : Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol- and Zotarolimus-Eluting Stents \(ISAR-TEST 5\) trial.](#)
Koch T, Lenz T, Joner M, Xhepa E, **Koppara T**, Wiebe J, Coughlan JJ, Aytekin A, Ibrahim T, Kessler T, Cassese S, Laugwitz KL, Schunkert H, Kastrati A, Kufner S; Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents (ISAR-TEST 5) Investigators.
Clin Res Cardiol. 2021 Oct;110(10):1586-1598. doi: 10.1007/s00392-021-01854-7. Epub 2021 Jun 22.
PMID: 34156521
3. [Outcomes of endovascular treatment for infrapopliteal peripheral artery disease based on the updated TASC II classification.](#)
Müller AM, Räßple V, Bradaric C, **Koppara T**, Kehl V, Fusaro M, Cassese S, Ott I, Kastrati A, Laugwitz KL, Ibrahim T.
Vasc Med. 2021 Feb;26(1):18-25. doi: 10.1177/1358863X20967091. Epub 2020 Dec 1.
PMID: 33256573
4. [Validation and application of OCT tissue attenuation index for the detection of neointimal foam cells.](#)
Nicol P, Hoppman P, Euller K, Xhepa E, Lenz T, Rai H, Jinnouchi H, Bulin A, Castellanos MI, Lahmann AL, **Koppara T**, Kastrati A, Joner M.
Int J Cardiovasc Imaging. 2021 Jan;37(1):25-35. doi: 10.1007/s10554-020-01956-9. Epub 2020 Aug 6.
PMID: 32761285
5. [10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents.](#)
Kufner S, Ernst M, Cassese S, Joner M, Mayer K, Colleran R, **Koppara T**, Xhepa E, Koch T, Wiebe J, Ibrahim T, Fusaro M, Laugwitz KL, Schunkert H, Kastrati A, Byrne RA; ISAR-TEST-5 Investigators.
J Am Coll Cardiol. 2020 Jul 14;76(2):146-158. doi: 10.1016/j.jacc.2020.05.026.
PMID: 32646563 Clinical Trial.
6. [Drug-coated balloons: Technical and clinical progress.](#)
Ang H, **Koppara TR**, Cassese S, Ng J, Joner M, Foin N.
Vasc Med. 2020 Dec;25(6):577-587. doi: 10.1177/1358863X20927791. Epub 2020 Jul 7.
PMID: 32634046

7. [Assessment of a pro-healing stent in an animal model of early neoatherosclerosis.](#)
Nicol P, Lutter C, Bulin A, Castellanos MI, Lenz T, Hoppmann P, Lahmann AL, Colleran R, Euler K, Steigerwald K, Neubauer S, Rechenmacher F, Ludwig BS, Weinmüller M, Kerch G, Guo L, Cheng Q, Acampado E, **Koppara T**, Kessler H, Joner M.
Sci Rep. 2020 May 19;10(1):8227. doi: 10.1038/s41598-020-64940-2.
PMID: 32427835
8. [Are we curing one evil with another? A translational approach targeting the role of neoatherosclerosis in late stent failure.](#)
Lenz T, Nicol P, Castellanos MI, Abdelgalil AAA, Hoppmann P, Kempf W, **Koppara T**, Lahmann AL, Rüscher A, Kessler H, Joner M.
Eur Heart J Suppl. 2020 Apr;22(Suppl C):C15-C25. doi: 10.1093/eurheartj/suaa006. Epub 2020 Apr 29.
PMID: 32368195
9. [Endovascular therapy of subclavian artery occlusive disease involving the vertebral artery origin.](#)
Schneider V, Dirschinger R, Wustrow I, Müller A, Cassese S, Fusaro M, Kastrati A, **Koppara T**, Bergmann K, Laugwitz KL, Ibrahim T, Bradaric C.
Vasa. 2020 Apr;49(3):205-213. doi: 10.1024/0301-1526/a000842. Epub 2020 Jan 6.
PMID: 31904303
10. [Incidence and predictors of stent thrombosis after endovascular revascularisation of the superficial femoral artery.](#)
Bradaric C, **Koppara T**, Müller A, Haller B, Ott I, Cassese S, Fusaro M, Kastrati A, Laugwitz KL, Ibrahim T.
EuroIntervention. 2019 Dec 20;15(12):e1107-e1114. doi: 10.4244/EIJ-D-19-00187.
PMID: 31355753
11. [Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.](#)
Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, Richardt G, Liebetau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flügel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Möllmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schühlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tölg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A; ISAR-REACT 5 Trial Investigators.
N Engl J Med. 2019 Oct 17;381(16):1524-1534. doi: 10.1056/NEJMoa1908973. Epub 2019 Sep 1.
PMID: 31475799
[Drug-free stents with Polyzene-F nanocoating: a promising compromise for those at high bleeding risk?](#)
12. **Koppara T**, Joner M.
EuroIntervention. 2019 Jul 20;15(4):e304-e307. doi: 10.4244/EIJV15I4A55.
PMID: 31322118
13. [Shedding Light Into Late Saphenous Vein Graft Failure.](#)
Koppara T, Joner M.
Cardiovasc Revasc Med. 2019 Jan;20(1):6-8. doi: 10.1016/j.carrev.2018.12.008.
PMID: 30744828
14. [Neoatherosclerosis in Patients With Coronary Stent Thrombosis: Findings From Optical Coherence Tomography Imaging \(A Report of the PRESTIGE Consortium\).](#)
Joner M, **Koppara T**, Byrne RA, Castellanos MI, Lewerich J, Novotny J, Guagliumi G, Xhepa E, Adriaenssens T, Godschalk TC, Malik N, Alfonso F, Tada T, Neumann FJ, Desmet W, Ten Berg JM, Gershlick AH, Feldman LJ, Massberg S, Kastrati A; Prevention of PRESTIGE Investigators.
JACC Cardiovasc Interv. 2018 Jul 23;11(14):1340-1350. doi: 10.1016/j.jcin.2018.02.029.
PMID: 30025727

15. [Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study.](#)
Koppara T, Tada T, Xhepa E, Kufner S, Byrne RA, Ibrahim T, Laugwitz KL, Kastrati A, Joner M.
 Int J Cardiol. 2018 May 1;258:42-49. doi: 10.1016/j.ijcard.2018.01.011.
 PMID: 29544956 Clinical Trial.
16. [Vascular response to percutaneous coronary intervention with biodegradable-polymer vs. new-generation durable-polymer drug-eluting stents: a meta-analysis of optical coherence tomography imaging trials.](#)
 Cassese S, Xhepa E, Ndrepepa G, Kufner S, Colleran R, Giacoppo D, **Koppara T**, Mankierious N, Byrne RA, Laugwitz KL, Schunkert H, Fusaro M, Kastrati A, Joner M.
 Eur Heart J Cardiovasc Imaging. 2018 Nov 1;19(11):1294-1301. doi: 10.1093/ehjci/jex334.
 PMID: 29300853 Review.
17. [Observations With Simultaneous 18F-FDG PET and MR Imaging in Peripheral Artery Disease.](#)
 Dregely I, **Koppara T**, Nekolla SG, Nährig J, Kuhs K, Langwieser N, Dzijan-Horn M, Ganter C, Joner M, Laugwitz KL, Schwaiger M, Ibrahim T.
 JACC Cardiovasc Imaging. 2017 Jun;10(6):709-711. doi: 10.1016/j.jcmg.2016.06.005. Epub 2016 Aug 24.
 PMID: 27568121
18. [Preclinical evaluation of a novel polyphosphazene surface modified stent.](#)
Koppara T, Sakakura K, Pacheco E, Cheng Q, Zhao X, Acampado E, Finn AV, Barakat M, Maillard L, Ren J, Deshpande M, Kolodgie FD, Joner M, Virmani R.
 Int J Cardiol. 2016 Nov 1;222:217-225. doi: 10.1016/j.ijcard.2016.07.181. Epub 2016 Jul 30.
 PMID: 27497098
19. [Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings.](#)
 Räber L, Brugaletta S, Yamaji K, O'Sullivan CJ, Otsuki S, **Koppara T**, Taniwaki M, Onuma Y, Freixa X, Eberli FR, Serruys PW, Joner M, Sabaté M, Windecker S.
 J Am Coll Cardiol. 2015 Oct 27;66(17):1901-14. doi: 10.1016/j.jacc.2015.08.853.
 PMID: 26493663
20. [Improving vessel healing with fully bioresorbable drug-eluting stents: more than a pipe dream?](#)
 Joner M, **Koppara T**, Virmani R, Byrne RA.
 Eur Heart J. 2016 Jan 14;37(3):241-4. doi: 10.1093/eurheartj/ehv537. Epub 2015 Oct 15.
 PMID: 26475833
21. [Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents.](#)
Koppara T, Cheng Q, Yahagi K, Mori H, Sanchez OD, Feygin J, Wittchow E, Kolodgie FD, Virmani R, Joner M.
 Circ Cardiovasc Interv. 2015 Jun;8(6):e002427. doi: 10.1161/CIRCINTERVENTIONS.115.002427.
 PMID: 26022535
22. [The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view.](#)
 Sanchez OD, Yahagi K, **Koppara T**, Virmani R, Joner M.
 Med Devices (Auckl). 2014 Dec 30;8:37-45. doi: 10.2147/MDER.S50051. eCollection 2015.
 PMID: 25565907
23. [Permanent and biodegradable polymer coatings in the absence of antiproliferative drugs in a porcine model of coronary artery stenting.](#)
Koppara T, Wittchow E, Byrne RA, Bayer G, Diener T, Joner M.
 EuroIntervention. 2016 Jan 22;11(9):1020-6. doi: 10.4244/EIJY14M10_08.
 PMID: 25317851

24. [Safety and efficacy of a potential treatment algorithm by using manual compression repair and ultrasound-guided thrombin injection for the management of iatrogenic femoral artery pseudoaneurysm in a large patient cohort.](#)
 Dzijan-Horn M, Langwieser N, Groha P, Bradaric C, Linhardt M, Böttiger C, Byrne RA, Steppich B, **Koppara T**, Gödel J, Hadamitzky M, Ott I, von Beckerath N, Kastrati A, Laugwitz KL, Ibrahim T. *Circ Cardiovasc Interv.* 2014 Apr;7(2):207-15. doi: 10.1161/CIRCINTERVENTIONS.113.000836. Epub 2014 Apr 1. PMID: 24692534
25. [Vertebral artery pseudoaneurysm complicating transaxillar aortic valve implantation.](#)
Koppara T, Fusaro M, Will A, Ibrahim T. *Eur Heart J.* 2013 Dec;34(45):3471. doi: 10.1093/eurheartj/eh253. Epub 2013 Jul 6. PMID: 23832551
26. [Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.](#)
Koppara T, Joner M, Bayer G, Steigerwald K, Diener T, Wittchow E. *Thromb Haemost.* 2012 Jun;107(6):1161-71. doi: 10.1160/TH12-01-0043. Epub 2012 Apr 26. PMID: 22535188
27. [Left main coronary artery compression in a young woman with Eisenmenger syndrome.](#)
Koppara T, Mehilli J, Hager A, Kaemmerer H. *Heart Asia.* 2011 Jan 1;3(1):13-5. doi: 10.1136/ha.2009.001578. eCollection 2011. PMID: 27325973
28. [Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention.](#)
 Wessely R, **Koppara T**, Bradaric C, Vorpahl M, Braun S, Schulz S, Mehilli J, Schömig A, Kastrati A; Contrast Media and Nephrotoxicity Following Coronary Revascularization by Angioplasty Trial Investigators. *Circ Cardiovasc Interv.* 2009 Oct;2(5):430-7. doi: 10.1161/CIRCINTERVENTIONS.109.874933. Epub 2009 Sep 22. PMID: 20031753 Clinical Trial.
29. [Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis.](#)
 Zohlnhöfer D, Dibra A, **Koppara T**, de Waha A, Ripa RS, Kastrup J, Valgimigli M, Schömig A, Kastrati A. *J Am Coll Cardiol.* 2008 Apr 15;51(15):1429-37. doi: 10.1016/j.jacc.2007.11.073. PMID: 18402895
30. [Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease.](#)
 Stefanescu A, Braun S, Ndrepepa G, **Koppara T**, Pavaci H, Mehilli J, Schömig A, Kastrati A. *Am Heart J.* 2008 Feb;155(2):356-60. doi: 10.1016/j.ahj.2007.10.017. Epub 2007 Dec 19. PMID: 18215608